9.4 Supplemental tables | MODELS TO INFORM THE SAFE COLLECTION AND TRANSFUSION OF DONATED BLOOD

Table 9.1: Parameter values for the microsimulation of transfusion-transmitted Zika outcomes. Where distribution parameters are not specified, the distribution was fit to the range, using the endpoints as 0.025 and 0.975 quantiles except in the case of triangular distribution, where the range was used as the minimum and maximum. Parameters without distributions were not varied in sensitivity analysis.
Probability	Age, low	Value (range); distribution
Zika fever [Russell 2019]		0.184 (0.0959–0.271); Beta
Guillain-Barré [Russell 2019]		0.000257; Beta (42, 1.634e+05)
Death from Guillain-Barré [Russell 2019]		0.0258; Beta (128, 4954)
Permanent disability from Guillain-Barré [Russell 2019]	0	0
15	0.0484 (0.0416–0.0548); Beta
20	0.121 (0.104–0.137); Beta
35	0.22 (0.208–0.232); Beta
65	0.488 (0.471–0.505); Beta
Penetrative sex [Russell 2019]	0	0
10	0.016 (0.00972–0.0273); Beta
15	0.214 (0.148–0.31); Beta
20	0.532 (0.46–0.621); Beta
25	0.765 (0.722–0.83); Beta
30	0.727 (0.682–0.785); Beta
40	0.624 (0.583–0.681); Beta
50	0.448 (0.402–0.503); Beta
60	0.397 (0.344–0.465); Beta
70	0.282 (0.221–0.36); Beta
Transmission from penetrative sex [Russell 2019]		0.1 (0.01–0.2); Tri
Congenital Zika syndrome [Russell 2019]		0.0343 (0.0095–0.195); Beta
Stillbirth after congenital transmission [Russell 2019]		0.07 (0.054–0.084); Tri
Recipient pregnant [Russell 2019]	0	0
15	0.0234
20	0.0573
25	0.0623
30	0.0541
35	0.0303
40	0.00769
45	0
Pregnancy multiplier for PSA [A]		1 (0.2–1.8); Tri
Partner pregnant [Russell 2019]	0	0
15	0.0442
20	0.108
25	0.118
30	0.102
35	0.0574
40	0.0146
45	0

Cost (2019 USD)	Age, low	Value (range); distribution
Annual productivity [U.S. Bureau of Labor Statistics 2020]	0	$32,268
25	$74,082
35	$96,581
45	$109,366
55	$88,342
65	$60,735
75	$38,786
Annual consumption [U.S. Bureau of Labor Statistics 2020]	0	$32,039
25	$56,457
35	$71,198
45	$75,387
55	$66,212
65	$56,268
75	$43,181
True positive test result [Russell 2019]		$92 ($76–$108); Tri
False positive test result [Russell 2019]		$92 ($76–$108); Tri
Zika fever in recipient (hospitalized) [Russell 2019]		$1,358 ($239–$2,477); Gamma
Zika fever in partner (non-hospitalized) [Russell 2019]		$109 ($56–$165); Gamma
Guillain-Barré [Russell 2019]		$61,676 ($51,001–$72,351); Gamma
Permanent disability from Guillain-Barré [Russell 2019]		$38,580 ($30,864–$46,295); Tri
Death from Guillain-Barré [Russell 2019]		$72,476 ($57,980–$86,971); Tri
Normal delivery [Russell 2019]		$25,386 ($18,803–$28,206); Tri
Infant testing [Russell 2019]		$243 ($194–$292); Tri
Mother testing [Russell 2019]		$505 ($404–$606); Tri
Stillbirth [Russell 2019]		$6,645 ($5,316–$7,973); Tri
Delivery with congenital Zika syndrome [Russell 2019]		$26,132 ($20,905–$31,358); Tri
Lifetime medical costs with congenital Zika syndrome [Russell 2019]		$4,358,764 ($3,487,011–$5,230,517); Tri

Health state utility	Age, low	Value (range); distribution
Baseline [Russell 2019]		0.9 (0.8–1); Tri
Zika fever, female recipient [Russell 2019]	0	0.57 (0.4–0.75); Beta
20	0.58 (0.44–0.72); Beta
35	0.63 (0.52–0.75); Beta
50	0.61 (0.48–0.74); Beta
65	0.59 (0.37–0.81); Beta
Zika fever, male recipient [Russell 2019]	0	0.5 (0.3–0.7); Beta
20	0.59 (0.4–0.77); Beta
35	0.58 (0.44–0.71); Beta
50	0.55 (0.41–0.68); Beta
65	0.54 (0.37–0.71); Beta
Guillain-Barré, year 1 [Russell 2019]		0.76 (0.349–0.987); Beta (3.818, 1.206)
Guillain-Barré, year 2 [Russell 2019]		0.87 (0.243–1); Beta (1.423, 0.2126)
Guillain-Barré, years 3-6 [Russell 2019]		0.99
Zika fever, partner [Russell 2019]		0.57 (0.54–0.6); Beta
Congenital Zika syndrome [Russell 2019]		0

Duration (years)	Age, low	Value (range); distribution
Zika fever, recipient [Russell 2019]		21 (1.4–66.2); Gamma (1.456, 14.42)
Zika fever, partner [Russell 2019]		7 (2.3–14.2); Gamma (5.201, 1.346)
Congenital Zika syndrome [Russell 2019]		79.8

Table 9.2: Parameter values for the microsimulation of transfusion-transmitted WNV outcomes. Where distribution parameters are not specified, the distribution was fit to the range, using them as 0.025 and 0.975 quantiles except in the case of triangular distribution, where the range was used as the minimum and maximum. Parameters without distributions were not varied in sensitivity analysis.
Probability	Age, low	Value (range); distribution
Immunocompromise in platelet recipient [Custer 2005]		0.5 (0.4–0.6); Tri
Immunocompromise in other recipient [A]		0.25 (0.2–0.3); Tri
Relative risk of disease, immunocompromised [Custer 2005]		2 (1.6–2.4); Tri
Clinical disease given WNV transmission [Shankar 2017]		0.25 (0.2–0.3); Tri
Disability from WNV fever, age 50+ [Shankar 2017]		0.11 (0.088–0.132); Tri
Disability from WNV fever, age under 50 [Shankar 2017]		0.00015 (0.00012–0.00018); Tri
Disability from meningitis [Shankar 2017]		0.22 (0.176–0.264); Tri
Disability from encephalitis [Shankar 2017]		0.45 (0.36–0.54); Tri
Disability from AFP [Shankar 2017]		0.22 (0.176–0.264); Tri
Symptomatic patient has WNV fever [Shankar 2017]	0	0.98 (0.784–1.18); Tri
60	0.97 (0.776–1.16); Tri
70	0.86 (0.688–1.03); Tri
Symptomatic patient has encephalitis [Shankar 2017]	0	0.00804 (0.00643–0.00965); Tri
20	0.00682 (0.00546–0.00818); Tri
30	0.0068 (0.00544–0.00816); Tri
40	0.00858 (0.00686–0.0103); Tri
50	0.0105 (0.00838–0.0126); Tri
60	0.0195 (0.0156–0.0234); Tri
70	0.105 (0.0841–0.126); Tri
80	0.111 (0.0887–0.133); Tri
Symptomatic patient has meningitis [Shankar 2017]	0	0.0114 (0.00914–0.0137); Tri
20	0.0124 (0.00994–0.0149); Tri
30	0.0119 (0.0095–0.0143); Tri
40	0.0101 (0.00811–0.0122); Tri
50	0.00798 (0.00638–0.00958); Tri
60	0.00819 (0.00655–0.00983); Tri
70	0.0273 (0.0218–0.0328); Tri
80	0.0218 (0.0175–0.0262); Tri
Symptomatic patient has AFP [Shankar 2017]	0	0.00054 (0.000432–0.000648); Tri
20	0.00076 (0.000608–0.000912); Tri
30	0.00132 (0.00106–0.00158); Tri
40	0.00128 (0.00102–0.00154); Tri
50	0.00154 (0.00123–0.00185); Tri
60	0.00228 (0.00182–0.00274); Tri
70	0.00756 (0.00605–0.00907); Tri
80	0.00728 (0.00582–0.00874); Tri
Death from WNV fever [Shankar 2017]	0	0
30	6e-04 (0.00048–0.00072); Tri
40	4e-04 (0.00032–0.00048); Tri
50	3e-04 (0.00024–0.00036); Tri
60	0.005 (0.004–0.006); Tri
70	0.016 (0.0128–0.0192); Tri
80	0.082 (0.0656–0.0984); Tri
Death from encephalitis [Shankar 2017]	0	0.015 (0.012–0.018); Tri
20	0.011 (0.0088–0.0132); Tri
30	0.014 (0.0112–0.0168); Tri
40	0.041 (0.0328–0.0492); Tri
50	0.058 (0.0464–0.0696); Tri
60	0.108 (0.0864–0.13); Tri
70	0.182 (0.146–0.218); Tri
80	0.336 (0.269–0.403); Tri
Death from meningitis [Shankar 2017]	0	0.005 (0.004–0.006); Tri
20	0.003 (0.0024–0.0036); Tri
30	0.004 (0.0032–0.0048); Tri
40	0.005 (0.004–0.006); Tri
50	0.006 (0.0048–0.0072); Tri
60	0.008 (0.0064–0.0096); Tri
70	0.045 (0.036–0.054); Tri
80	0.157 (0.126–0.188); Tri
Death from AFP [Shankar 2017]	0	0
30	0.036 (0.0288–0.0432); Tri
40	0.061 (0.0488–0.0732); Tri
50	0.086 (0.0688–0.103); Tri
60	0.091 (0.0728–0.109); Tri
70	0.194 (0.155–0.233); Tri
80	0.3 (0.24–0.36); Tri

Cost (2019 USD)	Age, low	Value (range); distribution
Initial cost, WNV fever [Staples 2014]		$9,426; Gamma (1.795, 3336)
Initial cost, meningitis [Staples 2014]		$9,434; Weibull (3.039, 7791)
Initial cost, encephalitis [Staples 2014]		$36,621; Pearson5 (2.161, 2.013e+04)
Initial cost, AFP [Staples 2014]		$95,125; Invgauss (5.593e+04, 2.223e+04)
Five-year cost, WNV fever [Staples 2014]		$2,082; Expo (0.001271)
Five-year cost, meningitis [Staples 2014]		$652; Expo (0.003184)
Five-year cost, encephalitis [Staples 2014]		$10,302; Expo (0.0001316)
Five-year cost, AFP [Staples 2014]		$66,632; Weibull (1.263, 6182)
Annual productivity [U.S. Bureau of Labor Statistics 2020]	0	$32,268
25	$74,082
35	$96,581
45	$109,366
55	$88,342
65	$60,735
75	$38,786
Annual consumption [U.S. Bureau of Labor Statistics 2020]	0	$32,039
25	$56,457
35	$71,198
45	$75,387
55	$66,212
65	$56,268
75	$43,181

Health state utility	Age, low	Value (range); distribution
Baseline in transfusion survivors [Shankar 2017]		0.9 (0.8–1); Tri
Multiplier for WNV fever [Shankar 2017]		0.52 (0.472–0.568); Tri
Multiplier for meningitis [Shankar 2017]		0.39 (0.35–0.43); Tri
Multiplier for encephalitis [Shankar 2017]		0.19 (0.17–0.21); Tri
Multiplier for AFP [Shankar 2017]		0.15 (0.135–0.165); Tri
Multiplier for disability caused by WNV fever [Shankar 2017]		0.92 (0.904–0.936); Tri
Multiplier for disability caused by meningitis [Shankar 2017]		0.88 (0.856–0.904); Tri
Multiplier for disability caused by encephalitis [Shankar 2017]		0.78 (0.736–0.824); Tri
Multiplier for disability caused by AFP [Shankar 2017]		0.68 (0.616–0.744); Tri

Duration (years)	Age, low	Value (range); distribution
Duration of WNV fever [Shankar 2017]		0.0178 (0.0027–0.0328); Tri
Duration of meningitis [Shankar 2017]		0.0123 (0.0055–0.0191); Tri
Duration of encephalitis [Shankar 2017]		0.0795 (0.0055–0.153); Tri
Duration of AFP [Shankar 2017]		0.0959 (0.0055–0.186); Tri
Duration of disability [Shankar 2017]		5.5 (4.4–6.6); Tri

Table 9.3: Number of donors and prevalence of Zika and West Nile virus by state-level donor group.
Geographic area	Year	Donors, N	WNV prevalence	Zika prevalence
Alabama (AL)1	2,017	153,726	9.8e-05	8.5e-07	5.8e-07	5.8e-07
2,018	153,338	5.1e-05	4.4e-07	1.8e-07	1.8e-07
2,019	153,098	7.1e-06	6.1e-08	0	0
Alaska (AK)	2,017	23,328	0	0	2.6e-06	2.6e-06
2,018	23,064	1.2e-05	1e-07	0	0
2,019	22,842	9.5e-06	8.2e-08	0	0
Arizona (AZ)	2,017	222,146	0.00013	1.1e-06	4e-07	4e-07
2,018	224,566	3.2e-05	2.8e-07	1.2e-07	1.2e-07
2,019	227,272	0.00017	1.4e-06	0	0
Arkansas (AR)	2,017	94,652	4.8e-05	4.1e-07	0	0
2,018	94,422	2.4e-05	2e-07	0	0
2,019	94,228	2.1e-05	1.8e-07	0	0
California (CA)	2,017	1,241,240	0.00011	9.7e-07	1.2e-06	1.2e-06
2,018	1,238,008	4.9e-05	4.2e-07	2.8e-07	2.8e-07
2,019	1,233,736	3.7e-05	3.2e-07	2e-08	2e-08
Colorado (CO)	2,017	176,980	9.7e-05	8.4e-07	1e-06	1e-06
2,018	178,550	0.00015	1.3e-06	0	0
2,019	179,812	0.00015	1.3e-06	0	0
Connecticut (CT)	2,017	112,690	6.7e-06	5.8e-08	2.1e-06	2.1e-06
2,018	112,048	5.7e-05	5e-07	0	0
2,019	111,324	1.9e-06	1.7e-08	0	0
Delaware (DE)	2,017	30,176	8.3e-06	7.2e-08	0	0
2,018	30,290	9.2e-05	8e-07	0	0
2,019	30,404	0	0	0	0
District of Columbia (DC)	2,017	21,916	4.6e-05	4e-07	4.1e-06	4.1e-06
2,018	22,010	0.00016	1.4e-06	0	0
2,019	22,036	6.9e-05	6e-07	0	0
Florida (FL)	2,017	661,126	1.9e-06	1.6e-08	5e-06	5e-06
2,018	666,488	1.5e-05	1.3e-07	2.9e-07	2.9e-07
2,019	670,624	6.4e-07	5.6e-09	0	0
Georgia (GA)	2,017	328,308	3.7e-05	3.2e-07	1.8e-07	1.8e-07
2,018	329,760	3e-05	2.6e-07	0	0
2,019	331,520	9.1e-06	7.9e-08	3.8e-08	3.8e-08
Hawaii (HI)	2,017	44,920	0	0	4e-06	4e-06
2,018	44,568	0	0	0	0
2,019	44,210	0	0	0	0
Idaho (ID)	2,017	54,172	0.00012	1e-06	0	0
2,018	54,918	8.1e-05	7e-07	0	0
2,019	55,800	4.3e-05	3.7e-07	1.1e-07	1.1e-07
Illinois (IL)	2,017	403,004	5.6e-05	4.9e-07	5.2e-07	5.2e-07
2,018	399,154	0.00012	1.1e-06	1e-07	1e-07
2,019	395,666	1.3e-05	1.1e-07	0	0
Indiana (IN)	2,017	209,974	3.1e-05	2.7e-07	4.3e-07	4.3e-07
2,018	210,054	4.6e-05	4e-07	0	0
2,019	210,208	4.1e-06	3.6e-08	0	0
Iowa (IA)	2,017	99,074	3e-05	2.6e-07	3e-07	3e-07
2,018	98,780	0.00029	2.5e-06	0	0
2,019	98,514	1.1e-05	9.5e-08	0	0
Kansas (KS)	2,017	91,732	7.4e-05	6.4e-07	6.5e-07	6.5e-07
2,018	91,336	0.00014	1.2e-06	0	0
2,019	90,966	1.4e-05	1.2e-07	0	0
Kentucky (KY)	2,017	140,410	1.8e-05	1.6e-07	4.3e-07	4.3e-07
2,018	139,958	2.4e-05	2.1e-07	0	0
2,019	139,500	1.5e-06	1.3e-08	0	0
Louisiana (LA)	2,017	147,294	9.1e-05	7.8e-07	2e-07	2e-07
2,018	146,186	0.00016	1.4e-06	0	0
2,019	145,154	3e-05	2.6e-07	0	0
Maine (ME)	2,017	42,090	0	0	7.1e-07	7.1e-07
2,018	42,010	1.3e-05	1.2e-07	0	0
2,019	41,972	0	0	0	0
Maryland (MD)	2,017	189,974	7.9e-06	6.9e-08	1.7e-06	1.7e-06
2,018	189,358	6.6e-05	5.7e-07	1.4e-07	1.4e-07
2,019	188,772	3.4e-06	3e-08	0	0
Massachusetts (MA)	2,017	216,336	7e-06	6e-08	1.7e-06	1.7e-06
2,018	215,926	6.3e-05	5.5e-07	6.3e-08	6.3e-08
2,019	215,212	5e-06	4.4e-08	0	0
Michigan (MI)	2,017	314,520	3.2e-05	2.8e-07	6.6e-07	6.6e-07
2,018	313,226	9.1e-05	7.9e-07	0	0
2,019	311,832	8.3e-06	7.2e-08	0	0
Minnesota (MN)	2,017	175,542	4.3e-05	3.7e-07	1.4e-06	1.4e-06
2,018	175,882	1e-04	8.7e-07	7.8e-08	7.8e-08
2,019	176,092	3.7e-06	3.2e-08	0	0
Mississippi (MS)	2,017	94,248	0.00017	1.5e-06	6.3e-07	6.3e-07
2,018	93,522	0.00015	1.3e-06	0	0
2,019	92,928	3.5e-05	3e-07	0	0
Missouri (MO)	2,017	192,584	2.5e-05	2.2e-07	3.1e-07	3.1e-07
2,018	192,050	3.3e-05	2.9e-07	0	0
2,019	191,636	3.4e-06	2.9e-08	0	0
Montana (MT)	2,017	33,192	8.3e-05	7.2e-07	0	0
2,018	33,276	0.00039	3.4e-06	0	0
2,019	33,372	1.9e-05	1.7e-07	0	0
Nebraska (NE)	2,017	60,422	0.00028	2.5e-06	9.9e-07	9.9e-07
2,018	60,412	0.0012	1e-05	0	0
2,019	60,400	0.0001	8.7e-07	1e-07	1e-07
Nevada (NV)	2,017	93,662	0.00018	1.6e-06	3.2e-07	3.2e-07
2,018	94,976	2.6e-05	2.3e-07	0	0
2,019	96,176	9.9e-05	8.6e-07	6.5e-08	6.5e-08
New Hampshire (NH)	2,017	42,536	5.9e-06	5.1e-08	0	0
2,018	42,462	0	0	0	0
2,019	42,456	0	0	0	0
New Jersey (NJ)	2,017	280,220	7.2e-06	6.2e-08	1.3e-06	1.3e-06
2,018	278,776	6.1e-05	5.3e-07	2.4e-07	2.4e-07
2,019	277,338	6.2e-06	5.4e-08	6.8e-08	6.8e-08
New Mexico (NM)	2,017	65,968	0.00013	1.1e-06	0	0
2,018	65,654	3e-05	2.6e-07	0	0
2,019	65,472	0.00013	1.2e-06	0	0
New York (NY)	2,017	617,792	2.1e-05	1.8e-07	3.1e-06	3.1e-06
2,018	612,716	4.5e-05	3.9e-07	1.8e-07	1.8e-07
2,019	607,420	5.7e-06	4.9e-08	3.1e-08	3.1e-08
North Carolina (NC)	2,017	323,828	6.2e-06	5.4e-08	7.4e-07	7.4e-07
2,018	325,698	8.6e-06	7.4e-08	1.3e-07	1.3e-07
2,019	327,482	6.6e-07	5.7e-09	0	0
North Dakota (ND)	2,017	23,808	0.00065	5.7e-06	0	0
2,018	23,782	0.0024	2.1e-05	0	0
2,019	23,794	8.2e-05	7.1e-07	0	0
Ohio (OH)	2,017	367,708	2.3e-05	2e-07	2.4e-07	2.4e-07
2,018	366,316	4.9e-05	4.3e-07	0	0
2,019	364,982	1.8e-06	1.5e-08	0	0
Oklahoma (OK)	2,017	123,982	8.5e-05	7.4e-07	2.4e-07	2.4e-07
2,018	123,614	4.1e-05	3.5e-07	0	0
2,019	123,554	1.2e-05	1.1e-07	0	0
Oregon (OR)	2,017	130,676	1.2e-05	1e-07	1.1e-06	1.1e-06
2,018	131,196	4.2e-06	3.7e-08	1e-07	1e-07
2,019	131,696	1.5e-05	1.3e-07	4.7e-08	4.7e-08
Pennsylvania (PA)	2,017	403,282	1.2e-05	1.1e-07	5.2e-07	5.2e-07
2,018	401,596	9e-05	7.8e-07	0	0
2,019	399,732	3.8e-06	3.3e-08	0	0
Puerto Rico (PR)	2,017	78,046	0	0	0.00043	4.2e-05
2,018	78,046	0	0	4.6e-05	4.6e-06
2,019	78,046	0	0	8.7e-06	8.6e-07
Rhode Island (RI)	2,017	33,292	1.5e-05	1.3e-07	2.7e-06	2.7e-06
2,018	33,202	8.4e-06	7.3e-08	0	0
2,019	33,078	0	0	0	0
South Carolina (SC)	2,017	158,354	2.9e-05	2.5e-07	3.8e-07	3.8e-07
2,018	159,502	2.6e-05	2.3e-07	0	0
2,019	160,764	1.3e-06	1.2e-08	0	0
South Dakota (SD)	2,017	27,528	0.00067	5.8e-06	0	0
2,018	27,566	0.0017	1.5e-05	0	0
2,019	27,622	8.6e-05	7.5e-07	0	0
Tennessee (TN)	2,017	211,574	3.6e-05	3.1e-07	2.8e-07	2.8e-07
2,018	212,442	1.6e-05	1.4e-07	0	0
2,019	213,236	3e-06	2.6e-08	0	0
Texas (TX)	2,017	892,342	3.8e-05	3.3e-07	1.8e-06	1.8e-06
2,018	898,152	4.5e-05	3.9e-07	6.1e-08	6.1e-08
2,019	905,372	7.2e-06	6.2e-08	1.4e-08	1.4e-08
Utah (UT)	2,017	97,796	0.00016	1.4e-06	1.2e-06	1.2e-06
2,018	98,934	3.1e-05	2.7e-07	2.8e-07	2.8e-07
2,019	100,104	4.5e-05	3.9e-07	6.2e-08	6.2e-08
Vermont (VT)	2,017	19,690	3.8e-05	3.3e-07	6.1e-06	6.1e-06
2,018	19,588	1.4e-05	1.2e-07	0	0
2,019	19,484	0	0	0	0
Virginia (VA)	2,017	266,914	1.2e-05	1.1e-07	7.8e-07	7.8e-07
2,018	266,706	5e-05	4.3e-07	5.1e-08	5.1e-08
2,019	266,514	4.9e-06	4.2e-08	2.3e-08	2.3e-08
Washington (WA)	2,017	234,108	1.4e-05	1.2e-07	1.9e-06	1.9e-06
2,018	236,042	3.5e-06	3.1e-08	0	0
2,019	237,768	4.5e-06	3.9e-08	0	0
West Virginia (WV)	2,017	57,302	4.4e-06	3.8e-08	5.2e-07	5.2e-07
2,018	56,606	9.8e-06	8.5e-08	0	0
2,019	55,958	0	0	0	0
Wisconsin (WI)	2,017	182,604	7e-05	6.1e-07	6.5e-07	6.5e-07
2,018	182,192	5e-05	4.4e-07	0	0
2,019	181,800	2.4e-06	2.1e-08	0	0
Wyoming (WY)	2,017	18,258	9.6e-05	8.4e-07	3.3e-06	3.3e-06
2,018	18,120	6.2e-05	5.3e-07	0	0
2,019	18,072	3.6e-05	3.1e-07	0	0
1Donor groups defined by state-level geographic area (also includes Washington D.C. and Puerto Rico), year, and season. Prevalence estimated by weighting the nucleic acid test-reactive donations by the case reports from the Centers for Disease Control and Prevention. Similar data for the donor groups stratified by 3-digit zip code are provided in a CSV file in a public repository (link in manuscript) due to table size.

Table 9.4: Zip codes for which testing was optimal in some PSA iterations, excluding West Nile virus testing during the high mosquito season.
	High mosquito season	Low mosquito season
MA	024	2,017	0.0	0.00	0.01	1.37	0.00	0.00
NY	107	2,017	0.0	0.00	0.31	8.20	0.00	0.00
NY	112	2,017	0.0	0.00	0.00	0.04	0.00	0.00
WV	255	2,017	0.0	0.00	1.03	21.53	0.00	0.00
NC	283	2,017	0.0	0.00	0.00	0.00	0.02	3.93
SC	293	2,017	0.0	0.00	0.00	0.00	0.04	5.64
FL	326	2,019	0.0	0.00	0.00	0.00	0.04	5.25
FL	328	2,017	0.0	0.00	0.00	0.09	0.00	0.00
FL	333	2,017	0.0	0.00	0.00	0.11	0.00	0.00
FL	337	2,017	0.0	0.00	0.00	0.15	0.00	0.00
KY	405	2,019	0.0	0.00	0.00	0.00	7.72	92.18
OH	440	2,017	0.0	0.00	0.00	0.00	0.00	0.21
MN	550	2,018	0.0	0.00	0.00	0.30	0.00	0.00
SD	574	2,017	0.0	0.00	0.00	0.04	0.00	0.00
SD	575	2,018	0.0	0.00	0.00	0.00	13.75	86.25
LA	703	2,017	0.0	0.00	0.00	0.00	8.10	91.88
TX	785	2,017	0.0	0.00	0.00	0.01	0.00	0.00
TX	794	2,017	0.0	0.00	0.00	0.00	1.72	40.11
AZ	852	2,019	0.0	0.00	0.00	0.00	0.00	0.08
NV	898	2,017	0.0	0.04	0.00	0.00	0.00	0.00
CA	920	2,017	0.0	0.05	0.00	0.00	0.00	0.00
CA	922	2,017	0.0	0.00	0.00	0.15	0.00	0.00
CA	923	2,017	0.0	0.06	0.00	0.00	0.00	0.00
CA	924	2,017	0.3	6.76	0.00	0.00	0.00	0.00
HI	967	2,017	0.0	0.09	0.00	0.00	0.00	0.00
WA	986	2,017	0.0	0.00	0.00	0.39	0.00	0.00

Table 9.5: Percent of time intervention part of optimal portfolio across 10,000 probabilistic sensitivity analysis iterations during high mosquito season in state-level analysis (no intervention was ever optimal during the low mosquito season).
State*	2017	2018	2019
AL1	WNV ID-NAT, 0.02% WNV MP-NAT, 3.43%
AZ	WNV ID-NAT, 0.35% WNV MP-NAT, 16.41%		WNV ID-NAT, 2.38% WNV MP-NAT, 48.07%
CA	WNV ID-NAT, 0.1% WNV MP-NAT, 8.55%
CO	WNV ID-NAT, 0.02% WNV MP-NAT, 3.06%	WNV ID-NAT, 1.43% WNV MP-NAT, 34.69%	WNV ID-NAT, 1.23% WNV MP-NAT, 31.77%
DC		WNV ID-NAT, 2.25% WNV MP-NAT, 47.01%	WNV MP-NAT, 0.09%
DE		WNV ID-NAT, 0.02% WNV MP-NAT, 2.03%
IA		WNV ID-NAT, 7.13% WNV MP-NAT, 91.75%
ID	WNV ID-NAT, 0.14% WNV MP-NAT, 10.62%	WNV MP-NAT, 0.62%
IL		WNV ID-NAT, 0.29% WNV MP-NAT, 14.63%
KS	WNV MP-NAT, 0.22%	WNV ID-NAT, 1.12% WNV MP-NAT, 29.54%
LA	WNV MP-NAT, 1.76%	WNV ID-NAT, 1.83% WNV MP-NAT, 41.67%
MA		WNV MP-NAT, 0.07%
MD		WNV MP-NAT, 0.08%
MI		WNV MP-NAT, 1.79%
MN		WNV ID-NAT, 0.02% WNV MP-NAT, 3.85%
MS	WNV ID-NAT, 2.49% WNV MP-NAT, 50%	WNV ID-NAT, 1.42% WNV MP-NAT, 33.94%
MT	WNV MP-NAT, 0.81%	WNV ID-NAT, 8.23% WNV MP-NAT, 91.75%
ND	WNV ID-NAT, 11.39% WNV MP-NAT, 88.61%	WNV ID-NAT, 44.56% WNV MP-NAT, 55.44%	WNV MP-NAT, 0.69%
NE	WNV ID-NAT, 6.94% WNV MP-NAT, 91.47%	WNV ID-NAT, 18.99% WNV MP-NAT, 81.01%	WNV ID-NAT, 0.02% WNV MP-NAT, 3.92%
NJ		WNV MP-NAT, 0.05%
NM	WNV ID-NAT, 0.36% WNV MP-NAT, 16.48%		WNV ID-NAT, 0.6% WNV MP-NAT, 21.01%
NV	WNV ID-NAT, 3.23% WNV MP-NAT, 59.05%		WNV ID-NAT, 0.02% WNV MP-NAT, 3.59%
OK	WNV MP-NAT, 1.01%
PA		WNV MP-NAT, 1.72%
PR	Zika ID-NAT, 0.94% Zika MP-NAT, 19.62%	Zika MP-NAT, 0.01%
SD	WNV ID-NAT, 11.54% WNV MP-NAT, 88.46%	WNV ID-NAT, 29.71% WNV MP-NAT, 70.29%	WNV MP-NAT, 1.08%
UT	WNV ID-NAT, 1.93% WNV MP-NAT, 42.71%
WI	WNV MP-NAT, 0.15%
WY	WNV ID-NAT, 0.02% WNV MP-NAT, 2.96%	WNV MP-NAT, 0.06%
1State and territory names are indicated using the STUSPS (State United States Postal Service) abbreviations. For all geographic areas not shown, the optimal policy was to use no intervention across all PSA iterations.

Table 9.6: Performance of optimal policy compared to universal testing and no testing in state-level analysis.
Year	Optimal	No intervention	Universal MP-NAT
Objective function value1
2017	$216M ($136M–$296M)	$217M ($137M–$297M)	$331M ($243M–$419M)
2018	$218M ($137M–$298M)	$221M ($140M–$301M)	$331M ($243M–$419M)
2019	$210M ($130M–$291M)	$210M ($130M–$291M)	$331M ($243M–$418M)
Test cost
2017	$0.90M ($0.30M–$4.93M)	$0M ($0M–$0M)	$124M ($89.50M–$159M)
2018	$0.73M ($0.61M–$3.45M)	$0M ($0M–$0M)	$124M ($89.50M–$159M)
2019	$0M ($0M–$1.40M)	$0M ($0M–$0M)	$124M ($89.50M–$159M)
Net monetary cost of released infectious donations
2017	$8.91M ($5.29M–$11.40M)	$10.40M ($7.31M–$14.40M)	$0.51M ($0.18M–$0.92M)
2018	$10.30M ($6.93M–$12.30M)	$14.20M ($9.88M–$19.60M)	$0.71M ($0.24M–$1.28M)
2019	$3.81M ($2.23M–$4.39M)	$3.81M ($2.66M–$5.26M)	$0.19M ($0.07M–$0.34M)
Zika residual risk
2017	3.10e-06 (1.48e-06–3.10e-06)	3.10e-06 (3.10e-06–3.10e-06)	6.20e-08 (1.68e-08–1.08e-07)
2018	2.90e-07 (2.91e-07–2.91e-07)	2.90e-07 (2.91e-07–2.91e-07)	5.81e-09 (1.57e-09–1.01e-08)
2019	4.84e-08 (4.84e-08–4.84e-08)	4.84e-08 (4.84e-08–4.84e-08)	9.68e-10 (2.62e-10–1.69e-09)
WNV residual risk
2017	2.19e-05 (1.13e-05–2.35e-05)	2.58e-05 (2.58e-05–2.58e-05)	1.29e-06 (4.82e-07–2.08e-06)
2018	2.60e-05 (1.91e-05–2.63e-05)	3.60e-05 (3.60e-05–3.60e-05)	1.80e-06 (6.74e-07–2.91e-06)
2019	9.69e-06 (5.64e-06–9.69e-06)	9.69e-06 (9.69e-06–9.69e-06)	4.85e-07 (1.82e-07–7.83e-07)
Zika-infectious donations released
2017	32.00 (15.30–32.00)	32.00 (32.00–32.00)	0.64 (0.17–1.11)
2018	2.99 (3.00–3.00)	3.00 (3.00–3.00)	0.06 (0.02–0.10)
2019	0.50 (0.50–0.50)	0.50 (0.50–0.50)	0.01 (0.00–0.02)
WNV-infectious donations released
2017	226.22 (116.75–242.58)	266.00 (266.06–266.06)	13.30 (4.98–21.49)
2018	268.84 (197.00–271.43)	372.00 (371.96–371.96)	18.59 (6.96–30.04)
2019	100.09 (58.29–100.09)	100.09 (100.09–100.09)	5.00 (1.87–8.09)
1Base case values reported with 95% credible interval from probabilistic sensitivity analysis. Comparator policies differ slightly from the zip code level analysis due to use of CDC data instead of AABB data for calculating prevalence.

			High mosquito season		Low mosquito season
State	Zip code	Year	Zika ID-NAT	Zika MP-NAT	Zika ID-NAT	Zika MP-NAT	WNV ID-NAT	WNV MP-NAT
MA	024	2,017	0.0	0.00	0.01	1.37	0.00	0.00
NY	107	2,017	0.0	0.00	0.31	8.20	0.00	0.00
NY	112	2,017	0.0	0.00	0.00	0.04	0.00	0.00
WV	255	2,017	0.0	0.00	1.03	21.53	0.00	0.00
NC	283	2,017	0.0	0.00	0.00	0.00	0.02	3.93
SC	293	2,017	0.0	0.00	0.00	0.00	0.04	5.64
FL	326	2,019	0.0	0.00	0.00	0.00	0.04	5.25
FL	328	2,017	0.0	0.00	0.00	0.09	0.00	0.00
FL	333	2,017	0.0	0.00	0.00	0.11	0.00	0.00
FL	337	2,017	0.0	0.00	0.00	0.15	0.00	0.00
KY	405	2,019	0.0	0.00	0.00	0.00	7.72	92.18
OH	440	2,017	0.0	0.00	0.00	0.00	0.00	0.21
MN	550	2,018	0.0	0.00	0.00	0.30	0.00	0.00
SD	574	2,017	0.0	0.00	0.00	0.04	0.00	0.00
SD	575	2,018	0.0	0.00	0.00	0.00	13.75	86.25
LA	703	2,017	0.0	0.00	0.00	0.00	8.10	91.88
TX	785	2,017	0.0	0.00	0.00	0.01	0.00	0.00
TX	794	2,017	0.0	0.00	0.00	0.00	1.72	40.11
AZ	852	2,019	0.0	0.00	0.00	0.00	0.00	0.08
NV	898	2,017	0.0	0.04	0.00	0.00	0.00	0.00
CA	920	2,017	0.0	0.05	0.00	0.00	0.00	0.00
CA	922	2,017	0.0	0.00	0.00	0.15	0.00	0.00
CA	923	2,017	0.0	0.06	0.00	0.00	0.00	0.00
CA	924	2,017	0.3	6.76	0.00	0.00	0.00	0.00
HI	967	2,017	0.0	0.09	0.00	0.00	0.00	0.00
WA	986	2,017	0.0	0.00	0.00	0.39	0.00	0.00